September - december with fin + oral & topical min + ru58841.
    12/23/2024

    From the encyclopedia
    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    RU58841 →

    a potent but unapproved and potentially problematic topical anti-androgen

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    💊 Finasteride (oral) 1mg 1x daily 4 months
    💧 Minoxidil (topical) 5% 2x daily 4 months
    💊 Minoxidil (oral) 2.5mg 2x daily 4 months
    💧 RU58841 (topical) 50mg 1x daily
    💊 Dutasteride (oral) some days
    • Microneedling 1.5 mm weekly to every 10-14 days
    💧 Keto Shampoo (topical)
    💧 Folliculitis Shampoo (topical) couple of weeks
    the tone is 😀 positive with impressive results.

    Other terms

    The user experienced hair regrowth using finasteride, oral and topical minoxidil, and RU58841, despite initial shedding. They also transitioned from finasteride to dutasteride and addressed scalp issues with a folliculitis shampoo.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results

      research CLINICAL UPDATES IN HAIR

      19 citations , January 1997 in “Dermatologic Clinics”
      This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.

      research Тіе Modern treatment of androgenetic alopecia

      February 2017 in “Vestnik dermatologii i venerologii”
      This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.

      research Therapeutic strategies for treating hair loss

      42 citations , March 2006 in “Drug Discovery Today: Therapeutic Strategies”
      This article discusses the need for rational strategies in developing hair loss drugs targeting specific events in hair follicle cycling, reporting no clinical findings but emphasizing the importance of understanding molecular controls.

      research Antiandrogens and Androgen Inhibitors

      November 2020 in “Elsevier eBooks”
      This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.